First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis.
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis.
复制标题
一线Durvalumab加上铂 - 亚替代与铂 - 估计剂，用于广泛的小细胞肺癌：成本效益分析。
DOI：
10.3389/fonc.2020.602185
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Cai H
中科院分区：
文献类型：
--
作者：
Zhang L;Hang Y;Liu M;Li N;Cai H
本研究的目的是从美国支付者的角度评估杜伐单抗加铂-依托泊苷与铂-依托泊苷作为小细胞肺癌一线治疗的成本效益。本研究以CASPIAN临床试验为基础，建立了三种健康状态、转移概率和安全性数据的分区生存模型。健康效用值主要来源于已发表的文献。只考虑了直接医疗费用。进行敏感性分析以评估每个质量调整生命年（QALY）的增量成本的稳健性。Durvalumab联合铂-依托泊苷与仅铂-依托泊苷相比，QALY增加了0.220。成本增加了78,198.75美元，每个QALY的增量成本增加了355,448.86美元。单向和概率敏感性分析表明，模型参数在有限的范围内变化，对结果没有显著影响。虽然杜伐单抗加铂依托泊苷可以改善生活质量，但也大大增加了医疗费用。在10万美元的支付意愿门槛下，durvalumab不具有成本效益的比较优势。
The aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer. This study established a partition survival model for three health states, metastasis probability, and safety data based on the CASPIAN clinical trial. The health utility value was mainly derived from the published literature. Only direct medical costs were considered. Sensitivity analyses were conducted to assess the robustness of the incremental cost per quality-adjusted life year (QALY). Durvalumab plus platinum–etoposide increased QALY by 0.220 compared to that observed with platinum–etoposide only. The cost increased by $78,198.75 and the incremental cost per QALY increased by $355,448.86. One-way and probability sensitivity analyses indicated that the model parameters varied within a limited range and had no significant effect on the results. Although durvalumab plus platinum–etoposide can improve quality of life, it also substantially increases the cost of medical treatment. Under a willingness-to-pay threshold of $100,000, durvalumab does not have a cost-effective comparative advantage.
登录
查看更多内容
影响因子：
20.4
作者：
Nicholson, Andrew G.;Chansky, Kari;Rami-Porta, Ramon
通讯作者：
Rami-Porta, Ramon
影响因子：
3.6
作者：
Briggs, Andrew H.;Weinstein, Milton C.;Paltiel, A. David
通讯作者：
Paltiel, A. David
影响因子：
5.3
作者：
Georgieva, Mina;da Silveira Nogueira Lima, Joao P.;Haaland, Benjamin
通讯作者：
Haaland, Benjamin
影响因子：
4.5
作者：
Goulart, Bernardo;Ramsey, Scott
通讯作者：
Ramsey, Scott
影响因子：
4
作者：
Hoyle MW;Henley W
通讯作者：
Henley W